Jasper Therapeutics (JSPR) Competitors $4.82 -0.22 (-4.37%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$4.88 +0.06 (+1.33%) As of 05/21/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JSPR vs. ACB, AQST, CMPX, DBVT, CRVS, IMMP, RNAC, AURA, CGC, and TSVTShould you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include Aurora Cannabis (ACB), Aquestive Therapeutics (AQST), Compass Therapeutics (CMPX), DBV Technologies (DBVT), Corvus Pharmaceuticals (CRVS), Immutep (IMMP), Cartesian Therapeutics (RNAC), Aura Biosciences (AURA), Canopy Growth (CGC), and 2seventy bio (TSVT). These companies are all part of the "pharmaceutical products" industry. Jasper Therapeutics vs. Aurora Cannabis Aquestive Therapeutics Compass Therapeutics DBV Technologies Corvus Pharmaceuticals Immutep Cartesian Therapeutics Aura Biosciences Canopy Growth 2seventy bio Jasper Therapeutics (NASDAQ:JSPR) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Do institutionals & insiders have more ownership in JSPR or ACB? 79.8% of Jasper Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 2.7% of Jasper Therapeutics shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility & risk, JSPR or ACB? Jasper Therapeutics has a beta of 2.74, suggesting that its stock price is 174% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Do analysts rate JSPR or ACB? Jasper Therapeutics currently has a consensus price target of $62.22, indicating a potential upside of 1,185.85%. Given Jasper Therapeutics' higher possible upside, research analysts plainly believe Jasper Therapeutics is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jasper Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Aurora Cannabis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.67 Is JSPR or ACB more profitable? Aurora Cannabis has a net margin of 0.42% compared to Jasper Therapeutics' net margin of 0.00%. Aurora Cannabis' return on equity of 0.59% beat Jasper Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Jasper TherapeuticsN/A -67.64% -58.53% Aurora Cannabis 0.42%0.59%0.42% Does the MarketBeat Community believe in JSPR or ACB? Aurora Cannabis received 336 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 90.57% of users gave Jasper Therapeutics an outperform vote while only 59.63% of users gave Aurora Cannabis an outperform vote. CompanyUnderperformOutperformJasper TherapeuticsOutperform Votes4890.57% Underperform Votes59.43%Aurora CannabisOutperform Votes38459.63% Underperform Votes26040.37% Which has higher valuation & earnings, JSPR or ACB? Aurora Cannabis has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioJasper TherapeuticsN/AN/A-$64.46M-$5.24-0.92Aurora Cannabis$320.81M0.93-$48.62M$0.05106.30 Does the media refer more to JSPR or ACB? In the previous week, Jasper Therapeutics had 17 more articles in the media than Aurora Cannabis. MarketBeat recorded 18 mentions for Jasper Therapeutics and 1 mentions for Aurora Cannabis. Aurora Cannabis' average media sentiment score of 0.38 beat Jasper Therapeutics' score of -0.13 indicating that Aurora Cannabis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jasper Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Aurora Cannabis 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryAurora Cannabis beats Jasper Therapeutics on 11 of the 18 factors compared between the two stocks. Get Jasper Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart JSPR vs. The Competition Export to ExcelMetricJasper TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.12M$2.94B$5.40B$8.53BDividend YieldN/A1.72%5.22%4.11%P/E Ratio-1.0131.1826.7419.97Price / SalesN/A407.34394.93122.22Price / CashN/A168.6838.2534.62Price / Book0.693.346.874.59Net Income-$64.46M-$72.17M$3.23B$248.18M7 Day Performance-0.23%6.07%5.01%2.15%1 Month Performance8.99%9.51%12.82%16.14%1 Year Performance-79.05%-27.14%17.63%8.06% Jasper Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)JSPRJasper Therapeutics2.1543 of 5 stars$4.82-4.4%$62.22+1,190.9%-79.1%$72.41MN/A-1.0220ACBAurora Cannabis0.6189 of 5 stars$5.06+4.3%N/A-26.8%$284.44M$320.81M101.221,340News CoverageAQSTAquestive Therapeutics1.2992 of 5 stars$2.85+2.2%$10.67+274.3%-28.6%$283.07M$57.56M-6.33160News CoveragePositive NewsAnalyst RevisionGap UpCMPXCompass Therapeutics3.678 of 5 stars$2.01+10.4%$13.13+553.0%+28.8%$277.95M$850,000.00-5.4320DBVTDBV Technologies2.7863 of 5 stars$10.13+3.1%$15.50+53.0%+48.6%$277.46M$15.73M-2.2580Gap DownCRVSCorvus Pharmaceuticals2.3989 of 5 stars$4.05-8.6%$16.33+303.3%+66.5%$276.08MN/A-4.3530Analyst ForecastHigh Trading VolumeIMMPImmutep1.5354 of 5 stars$1.87+1.1%$8.50+354.5%-39.9%$273.09M$5.14M0.002,021Gap DownRNACCartesian Therapeutics1.5334 of 5 stars$10.44+5.5%$42.50+307.1%-62.3%$270.78M$38.91M-0.2064News CoverageAnalyst RevisionGap UpAURAAura Biosciences2.4576 of 5 stars$5.35+2.3%$22.75+325.2%-14.2%$268.70MN/A-3.0950Earnings ReportInsider TradeGap UpCGCCanopy Growth1.4008 of 5 stars$1.46+11.5%$2.00+37.0%-82.2%$268.44M$276.75M-0.383,150Trending NewsTSVT2seventy bio1.5432 of 5 stars$5.00+0.2%$4.25-15.0%N/A$266.15M$37.86M-2.69440News Coverage Related Companies and Tools Related Companies Aurora Cannabis Alternatives Aquestive Therapeutics Alternatives Compass Therapeutics Alternatives DBV Technologies Alternatives Corvus Pharmaceuticals Alternatives Immutep Alternatives Cartesian Therapeutics Alternatives Aura Biosciences Alternatives Canopy Growth Alternatives 2seventy bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:JSPR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWarning: Prepare to Be Shocked by These PayoutsThere's a strategy out there paying up to 70% on tech stocks like Amazon, Tesla, and Microsoft—stocks that don...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredTrump’s Bitcoin Reserve is No Accident…How everyday investors are building crypto wealth (step-by-step guide) Don't wait. The window for maximum g...Crypto 101 Media | SponsoredTrump’s treachery I think Trump’s Treasury Secretary is destroying the stock market on purpose. And no one on Wall Street see...Porter & Company | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredSilver Is the New Oil—And the World’s Running DryElon's Next Market Move Could Send Silver Soaring Every industry Elon Musk touches explodes—from Tesla to S...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jasper Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jasper Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
